Health
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
BAAR, Switzerland, February 11, 2026--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.
About this update from Novocure Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2785,"height":407,"url":"https://media.zenfs.com/en/business-wire.com/6f7300b0b59a44e6f9845bc4fc771644"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_FV.44YGR5fwn2lmhWTg7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/6f7300b0b59a44e6f9845bc4fc771644","width":960,"height":140},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/hamNf1lgZl3H3uUdPIRB_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0zNTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/6f7300b0b59a44e6f9845bc4fc771644","width":1200,"height":175}},"lazy":false},{"type":"text","content":"Optune Pax concomitant with gemcitabine and nab-paclitaxel is the first treatment to be FDA approved in nearly 30 years for locally advanced pancreatic cancer","length":158,"tagName":"p","attribs":{}},{"type":"text","content":"Phase 3 PANOVA-3 trial showed a statistically significant improvement in overall survival (OS) and significantly extended time to pain progression in patients treated with Optune Pax","length":182,"tagName":"p","attribs":{}},{"type":"text","content":"Optune Pax is a wearable medical device that delivers Tumor Treating Fields (TTFields), alternating electric fields that disrupt cancer cell replication to cause cell death, providing a new treatment approach for pancreatic tumors","length":230,"tagName":"p","attribs":{}},{"type":"text","content":"BAAR, Switzerland, February 11, 2026--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax® for the treatment of adult patients with locally advanced pancreatic cancer concomitant with gemcitabine and nab-paclitaxel.","length":289,"tagName":"p"},{"type":"text","content":""In the Phase 3 PANOVA-3 trial, treatment with Optune Pax resulted in a statistically significant improvement in overall survival without adding to the systemic side effects commonly associated with existing therapies. It also significantly extended time to pain progression, helping to preserve overall quality of life, which is a priority when I am treating patients living with pancreatic cancer," said Vincent Picozzi, M.D., MMM, medical oncologist and investigator in the PANOVA-3 trial. &...